LAW OFFICES OF



Synnestvedt & Lechner llp

2600 ARAMARK TOWER IIOI MARKET STREET PHILADELPHIA, PA 19107-2950 TELEPHONE (215) 923-4466

FACSIMILE (215) 923-2189 E-MAIL synnlech@synnlech.com www.synnlech.com

October 6, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of G. Searfos III, M. Pagnoni, Y. Ivashchenko, K. Guo and K. Clark

Application No. 10/018,030 Filed September 23, 2002

Examiner: Not Yet Assigned

Group Art Unit 1623

VARIANTS OF TRAF2 WHICH ACT AS AN INHIBITOR OF TNF-AALPHA (TNFα) SIGNALING PATHWAY

(Attorney Docket No. P22,816-A USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence, along with any other papers indicated as being enclosed, is being deposited with the United States Postal Services, as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on October 6, 2004.

net M. Karmann

Mail Stop: Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §1.97(b), (c)

Sir:

It is requested respectfully that the information identified on the enclosed Form PTO-1449 (Modified) be made of record and considered with respect to the abovereferenced patent application. A copy of each item of information identified on the Form is enclosed. The Examiner is requested to indicate that each item on the enclosed Form PTO-1449 (Modified) has been considered by initialing and dating the enclosed Form and returning a copy of same to the undersigned.

This Information Disclosure Statement is filed before a first Office Action on the merits. Each item identified in this Information Disclosure Statement was first cited in the Supplementary European Search Report of July 12, 2004 (copy enclosed) for counterpart application number EP 920190.6.

Identification of information on the attached Form, or in this statement, is not an admission that such information is prior art to the invention claimed in the present application or that such information is in an analogous art area.

The Commissioner is authorized hereby to charge any fees or credit any overpayment associated with this Statement (copy enclosed) to Deposit Account Number 19-5425.

Respectfully submitted,

Patrick V. Kelly, Ph.D. Registration No. 34,638

Synnestvedt & Lechner LLP 2600 Aramark Tower 1101 Market Street Philadelphia, PA 19107 Telephone (215) 923-4466 Facsimile (215) 923-2189 FORMOTO-1449 (MODIFIED)

BADEFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.	10/018,030
FILING DATE	September 23, 2004
FIRST NAMED INVENTOR	G. Searfos III
ART UNIT	1623
EXAMINER NAME	Not Yet Assigned
ATTORNEY DOCKET NO.	P22,816-A USA

OTHER PUBLICATIONS

AA	Rothe et al., A Novel Family of Putative Signal Transducers Associated With the Cytoplasmic Domain of the 75 kDa Tumor Necrosis Factor Receptor, Cell, Vol. 78: p. 681-692 (August 26, 1994)
AB	Hsu et al., TRADd-TRAF2 and TRADD-FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways, Cell, Vol. 84: p. 299-308 (January 26, 1996)
AC	Rothe et al., TRAF2-Medicated Activation of NF- _k B by TNF Receptor 2 and CD40, PNAS Vol. 269: p 1424-1427 (September 8, 1995)
AD	Le, et al., CD30/TNF Receptor-Associated Factor Interaction: NF- _k B Activation and Binding Specificity, PNAS Vol. 93, p. 9699-9703 (September 1996)
AE	Hori et al., A Novel Domain in the CD30 Cytoplasmic Tail mediates NfkB Activation, International Immunology Vol. 10, No. 2, p. 203-210 (February 2, 1998)
AF	Duckett, et al., Inducgtion of Nuclear Factor B by the CD 30 Receptor is Mediated by TRAF1 and TRAF2, Mol. and Cell. Biol. Vol. 17 No. 3, p. 1535-1542 (March 1997)
AG	Dadgostar et al., An Intact zinc Ring Finger is Required for tumor Necrosis Factor Receptor-Associated Factor-Mediated Nuclear Factor- _k B Activation But Is Dispensable for c-Jun N-terminal Kinase Signaling, J. Biol. Chem. Vol. 272, No. 38, p. 24775-24780 (September 18, 1998)
АН	Cao et al., TRAF6 is a Signal Transducer for Interleukin-1, Nature, Vol. 383 p. 443-446 (October 1996)
AI	

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to
applicant.
Sheet 1 of 1
September 1, 2004